<DOC>
	<DOCNO>NCT01729455</DOCNO>
	<brief_summary>The purpose registry collect additional information regard side effect effectiveness BENLYSTA ( belimumab ) give lupus medicine adult active systemic lupus erythematosus ( SLE ) . Information collect serious event common may see long-term treatment . These event include death , cancer , serious infection infection interest , serious mental health problem . Information effectiveness BENLYSTA also collect .</brief_summary>
	<brief_title>Safety Effectiveness Belimumab Systemic Lupus Erythematosus Registry</brief_title>
	<detailed_description>The registry enroll 2 group patient . One group include patient currently take lupus medicine along intravenous BENLYSTA ( With BENLYSTA ) . The group include patient take lupus medicine take BENLYSTA ( Without BENLYSTA ) . For every 3 participant enrol registry , 2 take BENLYSTA 1 . After enrollment , change lupus medication , include start stop BENLYSTA , discretion physician , patient continue follow regardless change lupus medicine study completion . Physicians manage patient accordance medical judgment standard care . Data collect enrollment 6 month interval 5 year .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis active SLE . Autoantibodypositive . Current SLE treatment include BENLYSTA and/or immunosuppressant ( example , azathioprine , methotrexate , cyclophosphamide , mycophenolate , biologics ) . Key Have receive treatment investigational agent within past year . Are currently enrol placebocontrolled BENLYSTA ( belimumab ) clinical trial continuation trial belimumab use investigational agent . Have history BENLYSTA exposure , currently receive BENLYSTA . Current SLE treatment include antimalarial ( example , hydroxychloroquine ) steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Belimumab</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Lupus</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>